Ivacaftor is the first treatment that addresses the underlying cause of cystic fibrosis (CF) by enhancing cystic fibrosis conductance transmembrane regulatory (CFTR) function in the setting of class III and IV mutations. [1] [2] [3] In class III mutations, the CFTR channel is located at the correct site at the cell surface but fails to open and close normally. The G551D mutation is the most common class III mutation, with a worldwide prevalence of 4% to 5%. 4 There is significant regional variation. 5 The prevalence of the G551D mutation in the Cork CF Centre is 23%, making it uniquely placed to offer a single-center insight on treatment response. Ivacaftor treatment results in significant improvement in lung function (FEV 1 ), increase in BMI, improved respiratory symptoms, reduction in sweat chloride concentration, and reduction in pulmonary exacerbations in patients with CF with the G551D mutation. 1, 2 Chest CT changes, including mild bronchiectasis, can be demonstrated in people with CF who have a normal FEV 1 . CT imaging evidence of disease progression has been observed in individuals whose FEV 1 has remained stable over time. A small study using standard CT imaging protocols before and after 1 year of ivacaftor treatment demonstrated improvement. 6 Low-dose CT scanning has not been used prospectively to evaluate treatment effect. We assessed the effect of ivacaftor using low-dose chest CT imaging.
Microbiology studies have suggested subtle changes in the lung microbiome after commencement of ivacaftor 7 ; thus, we assessed the lung microbiota after treatment. Recent data have demonstrated no significant change in sputum cytokine levels after commencement of ivacaftor. We assessed the change in circulating inflammatory markers after treatment. We hypothesized that CFTR modulatory therapy may result in improvement in low-dose chest CT scans, circulating inflammatory mediators, and changes in the lung microbiota.
Methods
All patients with CF aged 6 years or older with at least one copy of the G551D mutation attending Cork CF Centre began ivacaftor treatment after March 2013 and were followed prospectively for a mean followup of 12 months. The prevalence of the G551D mutation at Cork CF Centre is 23%, with 51 of 220 patients carrying at least one copy of the G551D mutation. Thirty-three patients with the G551D mutation consented to participate. Eight children were too young to receive ivacaftor, six patients had already commenced ivacaftor either as part of a clinical trial or on a named patient (compassionate use) basis, two patients were post-lung transplantation, and three were undecided as to whether they wished to start treatment. According to the UK CF Trust annual report of 2015, there were 32 patients with the G551D mutation in Northern Ireland, representing 8% of the CF population. According to the CF Registry of Ireland annual report, there are 93 patients with the G551D mutation in the Republic of Ireland, representing 11.3% of the CF population. Thus, this patient group represents approximately one-quarter of patients with the G551D mutation on the island of Ireland. Ethical approval was obtained for the Clinical Outcome in Real-World Kalydeco (CORK) study from the Clinical Research Ethics Committee of the Cork Teaching Hospitals (ECM 4 [j] February, 7, 2013). Ivacaftornaive patients with CF attended for assessment when clinically stable. Spirometry was performed according to European Respiratory Society/American Thoracic Society guidelines using a MicroLab spirometer (CareFusion), which is calibrated on a regular basis. 8 Sweat-testing was performed using a Macroduct system (Wescor Inc) in accordance with manufacturer's guidelines. A modified shuttle walk test was performed at visits. Patients aged 14 years and older completed the Cystic Fibrosis Questionnaire Revised (CFQ-R), and for patients aged 6 to 14 years, the parents completed the caregiver CFQ-R. 9 Participants were assessed every 3 months after ivacaftor treatment. The number of courses of IV antibiotics administered for pulmonary exacerbations was recorded prospectively for 12 months after ivacaftor treatment and compared with the number of courses of IV antibiotics 12 months before commencing ivacaftor.
Radiology
Adapted ultra-low-dose chest CT imaging was performed (mean effective radiation dose, 0.08 mSv), using a previously validated protocol, 10 at baseline and after 3, 6, and 12 months of treatment in participants aged 16 years and older. Chest CT scans were scored by consensus between two experienced consultant radiologists using a Bhalla scoring system.
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Sputum Testing
Adult patients produced a sputum sample at baseline when clinically stable before commencing ivacaftor treatment and at clinic review every 3 months after ivacaftor treatment when the patients were able to expectorate.
Blood Samples
Blood samples were collected from all patients in bottles containing sodium citrate with the plasma layer separated and stored at -80 C. Circulating inflammatory markers, including interleukin (IL)-1b, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-a, and C-reactive protein (CRP), were measured using a multiplex enzyme linked immunosorbent assay (MesoScale Discovery platform) according to the manufacturer's guidelines. 12, 13 Molecular Detection: Illumina MiSeq Sequencing Processing of sputum samples and sequence library preparation are described in detail in e-Appendix 1. 16S rRNA marker gene sequencing was performed on the Illumina MiSeq platform (Illumina) targeting the V4 the hypervariable region of the 16S rRNA gene, as previously described.
14 Intrasample similarities/ differences were assessed through relative abundance changes in microbial taxa between visit time points, sample richness (number of counted taxa), and diversity (Shannon Wiener index).
Statistical Analysis
Data were analyzed using SPSS, version 22.0. A mean post-follow-up value was calculated for each parameter for each patient (mean of available values at 3, 6, 9, and 12 months), and this value was compared with the value obtained before commencing ivacaftor treatment. Blood inflammatory marker data were log 10 transformed before analysis. A paired sample t test was used to evaluate the mean change from baseline for normally distributed variables. A paired Wilcoxon signed rank test was used to evaluate the change in nonnormally distributed data. Repeated-measures analysis of variance (ANOVA) with a Bonferroni correction for multiple comparisons was used to compare changes in chest CT imaging score. The Pearson and Spearman rank correlation coefficients (as appropriate to the distribution) were used to evaluate correlation between clinical parameters, blood biomarkers, and chest CT imaging scores.
Results
Clinical Findings
Twenty adults and 13 pediatric patients participated. Table 1 summarizes baseline characteristics. The mean age of the cohort was 21.6 years, and 70% were male participants. The mean baseline FEV 1 % predicted was 75.21% (SD, 20.7). The mean baseline sweat chloride level was 101 mmol/L (SD, 14.7). The majority of patients (85%) had the F508del mutation as a second mutation. One patient was homozygous for the G551D mutation. All other patients had a class I or II mutation as the second mutation.
After commencement of therapy, a 10.3% mean increase in FEV 1 % predicted (P < .001) and a 58 mmol/L mean reduction in sweat chloride concentrations were observed after treatment (P < .001) (Fig 1) . After 1 year of treatment, 83% of patients had a sweat chloride level less than the level considered diagnostic for CF (60 mmol/L) (e-Figs 1, 2). No significant relationship was observed between the magnitude of change in FEV 1 and the magnitude of change in sweat chloride levels after 3, 6, 9, or 12 months of treatment (e -Fig 3) . A 76% reduction in pulmonary exacerbations requiring IV antibiotics was observed in the first year of therapy compared with the year before treatment, with a reduction in the mean number of exacerbations per patient from 0.88 to 0.21 (P ¼ .006). A significant 109-m mean increase in modified shuttle walk test (P ¼ .001) and a 1.2-kg/m 2 significant mean increase in BMI (P < .001) were observed after ivacaftor treatment (Fig 2) . These results are in keeping with those observed in previous studies. 1, 7 A 17.5 point mean increase in adult (P ¼ < .001) and an 8.8 point mean increase in caregiver-completed CFQ-R Respiratory Domain (P ¼ .08) were observed (e- Fig 4) . Changes in other domains of the CFQ-R can be found in e- Tables 1 and 2 .
Radiological Findings
Eighteen adults had low-dose chest CT scanning performed before ivacaftor treatment and after 3, 6, and 12 months of treatment, with CT findings summarized in Table 2 . In this group, a 12% mean increase in FEV 1 % predicted (P < .01), a 58 mmol/L mean reduction in sweat chloride levels (P < .01), and a 1.6 kg/m 2 mean increase in BMI were observed. Repeated-measures ANOVA demonstrated significant mean reductions in total Bhalla score (P < .01), peribronchial thickening (P ¼ .035), and extent of mucous plugging (P < .01) with treatment. There was no statistically significant change in the severity and extent of bronchiectasis, number of bullae, emphysema, presence of sacculation or abscesses, and the generations of bronchial divisions involved in bronchiectasis and plugging (Table 2) . Post hoc testing using a Bonferroni correction for multiple comparisons demonstrated significant improvement from baseline in total Bhalla score (P < .01) and mucous plugging (P < .01) after 3, 6, and 12 months. e-Figures 5 and 6 illustrate representative chest CT scans before and after treatment.
Culture-Independent Analysis
Analysis of airway microbial community composition was performed for a subset of patients (n ¼ 14) who provided a sputum sample for pretreatment analysis and at least one posttreatment sputum sample. For patients with more than one posttreatment sample, we analyzed the last sample collected, representing the change from baseline (pretreatment sample). Five main taxa, which accounted for > 1% of the total sequence reads in each of the corresponding samples, dominated the overall community in both pretreatment and posttreatment sample groups (Fig 3A) . Following treatment, there was a 30% (68%-53%) reduction in the relative proportion of Pseudomonas species within the community. In contrast, there was an overall increase in the relative proportion of Streptococcus species, Rothia species, Haemophilus species, and Prevotella species, ranging from 19% to 80% posttreatment (Fig 3A) .
Taxonomic richness (ie, the number of taxa present in a sample at a particular taxonomic level) increased significantly following treatment (P ¼ .031; paired Student t test) (Fig 3B) . We observed an increase in community diversity posttreatment, but this did not reach statistical significance (P ¼ .069; Mann-Whitney test) (Fig 3C) .
Circulating Inflammatory Markers
Significant reductions in circulating log 10 IL-6 (P < .01), log 10 IL-8 (P < .01), log 10 IL-10 (P < .01), log 10 IL-1b (P < .01), and log 10 CRP (P ¼ .015) were observed after treatment (e- Fig 6) . A nonsignificant reduction in log 10 TNF-a was observed after commencement of treatment (P ¼ .06).
Discussion
This is the first study to use ultra-low-dose chest CT scanning (mean dose, 0.08 mSv per scan) to serially examine the ivacaftor response over a 1-year period, allowing an assessment of the key mechanisms underlying clinical response and assessing its utility in a clinical setting to monitor CFTR modulatory therapy response. Significant improvements in ultra-low-dose chest CT scans were observed early, after 3 months of treatment, with further improvements noted after 1 year of therapy. The greatest improvements on chest CT images were in the extent of mucous plugging. This is consistent with in vitro studies in which ivacaftor enhanced airway surface liquid and ciliary beat frequency. 15, 16 The limitation of using FEV 1 to assess Thus, we suggest that ultra-low-dose chest CT scanning may represent a biomarker of early and sustained treatment response post-CFTR modulation. It may be a useful potential new outcome measure in clinical care, with broad application across CF sites. The growing awareness that patients with CF are at increased risk of certain neoplasms supports using low-dose CT scanning to reduce this risk. 18, 19 There was no statistically significant change in bronchiectasis on chest CT scans after ivacaftor therapy in contrast to a previous smaller study that included adults and children. 6 Our study supports the finding that in established lung damage, bronchiectasis is not reversible with CFTR modulatory therapy. It remains to be established if treatment with ivacaftor will delay or prevent the development of bronchiectasis in those who start treatment early.
We observed significant improvements in lung function, weight, walk test, and CFQ-R after commencement of ivacaftor treatment. The improvement in lung function was in keeping with that observed in the clinical trials and larger than that observed in other observational studies in people receiving treatment outside of clinical trials. 7 This may be due to the fact that our cohort had a lower baseline FEV 1 than those in other observational studies. The improvement in the respiratory domain of the CFQ-R was larger than that observed in the clinical trials. 1, 2 In keeping with previous work (n ¼ 24), no correlation was observed between the change in FEV 1 % predicted and change in sweat chloride levels at any of the time points, suggesting that it is a poor marker of treatment response. 20 We have demonstrated that following ivacaftor treatment, significant changes occur in the microbial community composition. The reduction in the relative abundance of members of Pseudomonas species is in The difference between normally distributed variables (richness) was evaluated using a paired t test. Difference between nonnormally distributed variables (Shannon Weiner diversity) was assessed using the Mann-Whitney test. P < .05 denotes statistical significance.
keeping with previous data. 7 The increase in Streptococcus species, as well as in the obligate anaerobic taxa Prevotella species and Veillonella species, demonstrates a potentially important clinical trend. The increased taxonomic richness and movement toward increased community diversity posttreatment is important given the previous work demonstrating a relationship between greater lung microbial diversity and better lung function. 21 Significant changes in the community composition of the airway microbiota in patients with CF have been shown to occur during the progression of the disease. 22 These changes include a narrowing in the spectrum of bacterial taxa, which is associated with a reduction in taxonomic richness and community diversity. The reason behind such a change in the community composition has been hard to elucidate and is multifactorial, although increased patient age and antimicrobial treatment burden in chronically colonized patients 23 has been shown to play a significant part. 21, 23 The subtle reversal toward a more "stable" microbiota similar to a "healthier" CF lung microbiome is important and may reflect disease reversal. That said, a significant 76% reduction in IV antibiotic requirements was observed in the year after ivacaftor treatment, which would also contribute to this finding. Changes within the lung environment may alter the lung environment sufficiently to driving such change. 24 We observed a significant reduction in a number of circulating inflammatory markers. This "real-world" finding is consistent with the results from a group of patients in the clinical trials that demonstrated a significant reduction in the circulating neutrophil count as well as IL-8, CRP, and IgG levels after 24 weeks of treatment. 25 That said, another real-world cohort failed to demonstrate a significant change in sputum cytokine levels in patients with CF treated with ivacaftor. 7 Inflammation in the CF lung is characterized by an excess influx of polymorphonuclear neutrophils. [26] [27] [28] [29] Exaggerated inflammation develops early in the course of CF, with elevated levels of inflammatory markers being demonstrated in the lungs of infants with CF in the absence of overt infection. 26, 27, [30] [31] [32] [33] Previous studies have demonstrated elevated levels of circulating inflammatory markers, including IL-2, IL 6, IL-8, and TNF-a, in patients with CF compared with control cohorts. [34] [35] [36] [37] [38] [39] Similarly, some studies have demonstrated a reduction in circulating inflammatory markers after antibiotic therapy for pulmonary exacerbations. 34 Whether the reduction seen in our study is solely due to a decrease in pulmonary exacerbations observed in our cohort or augmented by potential changes in immune function postrestoration of CFTR function remains to be evaluated given that studies have demonstrated improved neutrophil function after ivacaftor therapy. 40, 41 Given the sustained improvements in chest CT images observed from 3 months after commencement of ivacaftor treatment (in particular, improved mucous plugging and peribronchial thickening), we suggest that enhanced mucus clearance is a key mechanism underlying the increase in lung function and reduction in pulmonary exacerbations observed in patients treated with ivacaftor. This is consistent with in vitro studies in which ivacaftor resulted in improved airway surface liquid and ciliary beat frequency. 15, 16 The subsequent improvement in symptoms, reduction in circulating inflammatory markers, and subtle changes in the lung microbiome are likely secondary factors contributing to this improvement.
Limitations
A limitation of this study is that it is observational in nature without a control group who did not receive ivacaftor treatment. However, the benefits of ivacaftor relative to placebo have been well demonstrated in existing trials; the observed improvements are similar to those reported in the trials cited here and would be disproportionate to changes expected in an untreated cohort. We avoided recruitment sample-related variability given that we included the entire cohort of patients attending our designated referral center for the region. All eligible patients received the drug, as it was funded by the state and not dependant on health insurance status.
Conclusions
This study demonstrates sustained improvement after ivacaftor treatment across multiple modalities of assessment, including multiple clinical parameters, ultra-low-dose chest CT imaging, blood inflammatory markers, and the lung microbiome. It suggests the potential utility of ultra-low-dose chest CT imaging as an approach for assessing treatment response.
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